This is a working overview of immunomodulator, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-17 and is reviewed periodically as new material appears.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Assessed by visual inspection at release |
| Solubility class | Freely soluble in water | Aqueous buffers near neutral pH |
| Typical storage temperature | Minus 20 degrees Celsius | Lyophilized, desiccated, protected from light |
| Typical analytical method | Reverse-phase HPLC with mass spectrometry | Used together for purity and identity |
| Common synonyms | T-alpha-1; thymalfasin | Older reports use several designations |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
== Licensing and partnerships == In July 2025, IGI entered a global licensing agreement with AbbVie for ISB 2001, a trispecific antibody in Phase 1 clinical trials for relapsed or refractory multiple myeloma. AbbVie obtained exclusive rights in North America, Europe, Japan, and Greater China, while Glenmark retained rights in India and other emerging markets. The deal included an upfront payment of $700 million, with potential milestones of up to $1.225 billion and tiered royalties on net sales. Glenmark has also in-licensed established oncology drugs. In September 2025 it licensed trastuzumab rezetecan from Hengrui Pharma for selected markets in a deal valued at up to $1.1 billion. In December 2025, Glenmark Specialty S.A. in-licensed aumolertinib from Hansoh Pharma for multiple regions. Aumolertinib had previously received approvals from the Medicines and Healthcare products Regulatory Agency and China's National Medical Products Administration for lung cancer treatment.
== History == Threonine was the last of the 20 common proteinogenic amino acids to be discovered. It was discovered in 1935 by William Cumming Rose, collaborating with Curtis Meyer. The amino acid was named threonine because it was similar in structure to threonic acid, a four-carbon monosaccharide with molecular formula C4H8O5.
==== Speech by Pedro Castillo ==== Against the backdrop of the ongoing political crisis, with parliamentary groups refusing to grant confidence to the government and even loyal ministers Roberto Sánchez and Hernando Cevallos expressing dissatisfaction, President Pedro Castillo gave a speech at 6:00 p.m. on 4 February 2022. In it, he announced a cabinet reshuffle and reorganization, without specifying whether he intends to replace the president of the council. At the time of the speech, a demonstration was taking place in front of the Government Palace demanding the resignation of Héctor Valer and against the appointment of the Minister of Women Katy Ugarte, who had spoken out against education in gender history and LGBT, in April 2021.
Sources: en.wikipedia.org
This results in white woolly appearance and more pleasant aroma compared with tempeh made with commercial starter containing only Rhizopus oligosporus. Famously these variant tempeh are found in Malang and Purwokerto in the 1960s, because Malang is located in a cool plateau, and tempeh made with Rhizopus oligosporus resulted in less compact and more alcoholic-smelling tempeh, while Rhizopus arrhizus required lower optimum temperature which made it more ideal. However the widespread use of commercial starter resulted in most tempeh in Java only containing Rhizopus oligosporus, with few traditionally made tempeh outside Java still containing Rhizopus arrhizus and Rhizopus delemar.
Wagyu (Japanese: 和牛, Hepburn: wagyū, lit. 'Japanese cattle') is not the name of a single cattle breed. Today, the term usually refers to four established Japanese breeds of beef cattle: the Japanese Black, Japanese Brown, Japanese Polled, and Japanese Shorthorn. Historically, it was also used for native Japanese cattle; the surviving Mishima and Kuchinoshima cattle populations are not included among the four modern breeds. Beginning in the late nineteenth century, these breeds were developed from regional native cattle crossed with imported stock. The timing of crossbreeding and the imported breeds involved varied by breed and region. The resulting cattle were later established as distinct breeds through selection and closed breeding. The Japanese Black accounts for more than 90% of Wagyu cattle raised in Japan and is the main source of the highly marbled beef commonly associated with Wagyu. Its beef has finely distributed intramuscular fat known as sashi, a high proportion of monounsaturated fatty acids, and a distinctive sweet aroma that develops during cooking. The other three breeds generally produce less heavily marbled beef. Regional names such as Kobe beef, Matsusaka beef, Ōmi beef, and Yonezawa beef refer to brands defined by geographical origin and production or quality standards, not to additional cattle breeds. In Japan, beef carcasses are graded separately for meat yield and meat quality.
Japanese and Korean sea-farmers have grown wakame for centuries, and are still both the leading producers and consumers. Wakame has also been cultivated in France since 1983, in sea fields established near the shores of Brittany. Wild-grown wakame is harvested in Tasmania, Australia, and then sold in restaurants in Sydney and also sustainably hand-harvested from the waters of Foveaux Strait in Southland, New Zealand and freeze-dried for retail and use in a range of products.
=== Sublima === In 2019, Cave founded Sublima Pharmaceuticals in an effort to develop the first non-hormonal birth control in the United States. She made this decision after having some side effects from her previous birth control pill. After three to four doctors and a span of six months, they figured out that the hormonal birth control was the problem. Sublima is still in early stages. Cave is expecting the fundraise after the drug gets approved by the FDA. The drug is currently in Phase Three of clinical trials.
Sources: en.wikipedia.org
Reconstituted solutions are typically kept refrigerated at two to eight degrees Celsius when used within a short window, or frozen in aliquots for longer periods. Repeated freeze-thaw cycles are avoided because they can reduce recovery of intact peptide.
It establishes that the measured mass matches the expected value for the intact molecule. It also helps detect modifications such as oxidation or truncation that shift the mass by a known amount.
Cycling between frozen and liquid states can promote aggregation and adsorption to container walls. Dividing a stock into single-use aliquots limits the number of cycles a given vial undergoes.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.